Genetic signature and treatment of pediatric high‑grade glioma

Guidi,Milena; Giunti,Laura; Buccoliero,Anna Maria; Caporalini,Chiara; Censullo,Maria Luigia; Galli,Luisa; Genitori,Lorenzo; Sardi,Iacopo

doi:10.3892/mco.2021.2232

Genetic signature and treatment of pediatric high‑grade glioma

Authors:
- Milena Guidi
- Laura Giunti
- Anna Maria Buccoliero
- Chiara Caporalini
- Maria Luigia Censullo
- Luisa Galli
- Lorenzo Genitori
- Iacopo Sardi
View Affiliations

Affiliations: Neuro‑Oncology Unit, Department of Pediatric Oncology, Meyer Children's University Hospital, I‑50139 Florence, Italy, Medical Genetics Unit, Meyer Children's University Hospital, I‑50139 Florence, Italy, Pathology Unit, Meyer Children's University Hospital, I‑50139 Florence, Italy, Department of Health Sciences, University of Florence, I‑50139 Florence, Italy, Neurosurgery Unit, Meyer Children's University Hospital, I‑50139 Florence, Italy
Published online on: February 12, 2021 https://doi.org/10.3892/mco.2021.2232
Article Number: 70

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pediatric high‑grade glioma (HGG) is a type of malignancy that carries a poor prognosis. The genetic analysis of HGGs has previously identified useful mutations, the targeting of which has improved prognosis. Thus, further research into the more common mutations, such as H3 histone variants (HIST1H3B and H3F3A) and BRAF V600E, may be useful in identifying tumors with different prognoses, as the mutations are considered to drive two distinct oncogenic programs. The present study performed a retrospective analysis of pediatric HGGs. In total, 42 cases of HGG, including 32 cases (76.1%) of anaplastic astrocytoma and 10 cases (23.8%) of glioblastoma multiforme (GBM), were assessed. The median age of the patients was 7 years (range, 0‑32 years). Mutations on histone H3, in particular the K27M and G34R mutations in the distinct variants HIST1H3B and H3F3A, in addition to the presence of the BRAF V600E mutation, were analyzed in 24 patients. The H3F3A K27M mutation was identified in 7 patients (29.1%), while the HIST1H3B K27M mutation was only observed in 1 patient with GBM. In addition, 5 patients harbored a BRAF V600E mutation (21%), while the H3F3A G34R mutation was not recorded in any of the patients. The overall survival of the wild‑type patients at 20 months was 68% [confidence interval (CI): 38‑85%] compared with 28% (CI: 0.4‑60%) in patients with the H3F3A K27M mutation. These results suggested that patients with the H3F3A K27M mutation had a worse prognosis compared with wild‑type patients (P=0.0045). Moreover, 3/5 patients with the BRAF V600E mutation had HGGs that were derived from a previous low‑grade glioma (LGG; P=0.001). In conclusion, these results suggested that histone H3 mutations may help predict the outcome in patients with HGG. In addition, the BRAF V600E mutation was found to be associated with an increased risk of anaplastic progression. The novel data of the present study may help better define the clinical and radiological characteristics of glioma.

View Figures

View References

1	Merchant TE, Pollack IF and Loefﬂer JS: Brain tumors across the age spectrum: Biology, therapy, and late effects. Semin Radiat Oncol. 20:58–66. 2010.PubMed/NCBI View Article : Google Scholar
2	Gielen GH, Gessi M, Hammes J, Kramm CM, Waha A and Pietsch T: H3F3A K27M mutation in pediatric CNS tumors: A marker for diffuse high-grade astrocytomas. Am J Clin Pathol. 139:345–349. 2013.PubMed/NCBI View Article : Google Scholar
3	Bouffet E, Tabori U, Huang A and Bartels U: Possibilities of new therapeutic strategies in brain tumors. Cancer Treat Rev. 36:335–341. 2010.PubMed/NCBI View Article : Google Scholar
4	Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM, Martinez D, Perry A, Lewis PW, Thompson CB and Judkins AR: A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol. 128:743–753. 2014.PubMed/NCBI View Article : Google Scholar
5	Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, et al: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 482:226–231. 2012.PubMed/NCBI View Article : Google Scholar
6	Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, et al: A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 125:315–326. 2006.PubMed/NCBI View Article : Google Scholar
7	Vanan MI, Underhill DA and Eisenstat DD: Targeting epigenetic pathway in the treatment of pediatric diffuse (high grade) gliomas. Neurotherapeutics. 14:274–283. 2017.PubMed/NCBI View Article : Google Scholar
8	Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pagès M, Taylor KR, Saulnier P, Lacroix L, et al: Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 130:815–827. 2015.PubMed/NCBI View Article : Google Scholar
9	Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, et al: Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol. 35:2934–2941. 2017.PubMed/NCBI View Article : Google Scholar
10	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
11	Rheinbay E, Louis DN, Bernstein BE and Suvà ML: A tell-tail sign of chromatin: Histone mutations drive pediatric glioblastoma. Cancer Cell. 21:329–331. 2012.PubMed/NCBI View Article : Google Scholar
12	Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, et al: Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 44:251–253. 2012.PubMed/NCBI View Article : Google Scholar
13	Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, et al: K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 124:439–447. 2012.PubMed/NCBI View Article : Google Scholar
14	Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, et al: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 22:425–437. 2012.PubMed/NCBI View Article : Google Scholar
15	Fontebasso AM, Liu XY, Sturm D and Jabado N: Chromatin remodeling defects in pediatric and young adult glioblastoma: A tale of a variant histone 3 tail. Brain Pathol. 23:210–216. 2013.PubMed/NCBI View Article : Google Scholar
16	Aihara K, Mukasa A, Gotoh K, Saito K, Nagae G, Tsuji S, Tatsuno K, Yamamoto S, Takayanagi S, Narita Y, et al: H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro Oncol. 16:140–146. 2014.PubMed/NCBI View Article : Google Scholar
17	Buczkowicz P, Bartels U, Bouffet E, Becher O and Hawkins C: Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: Diagnostic and therapeutic implications. Acta Neuropathol. 128:573–581. 2014.PubMed/NCBI View Article : Google Scholar
18	Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, Bison B, Claviez A, van Vuurden DG, von Bueren AO, et al: Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol. 20:123–131. 2018.PubMed/NCBI View Article : Google Scholar
19	Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA, et al: Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 129:669–678. 2015.PubMed/NCBI View Article : Google Scholar
20	Lu VM, Alvi MA, McDonald KL and Daniels DJ: Impact of the H3K27M mutation on survival in pediatric high-grade glioma: A systematic review and meta-analysis. J Neurosurg Pediatr. 23:308–316. 2018.PubMed/NCBI View Article : Google Scholar
21	Pratt D, Natarajan SK, Banda A, Giannini C, Vats P, Koschmann C, Mody R, Chinnaiyan A and Venneti S: Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. Acta Neuropathol. 135:299–301. 2018.PubMed/NCBI View Article : Google Scholar
22	Felix F and Fontenele J: Valproic acid may be tested in patients With H3F3A-mutated high-grade gliomas. J Clin Oncol. 34:3104–3105. 2016.PubMed/NCBI View Article : Google Scholar
23	Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, et al: Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 20:1394–1396. 2014.PubMed/NCBI View Article : Google Scholar